Latest News

06.15.21

Eyenovia Highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress, and Licensing Agreements

Source: Eyenovia

06.15.21

Visus Therapeutics Announces Executive Leadership Appointments in Operations, Research, Clinical Operations and Intellectual Property

Source: Visus Therapeutics

06.14.21

Schwind Receives “SME Innovation Award“ in Germany

Source: Schwind eye-tech-solutions

06.14.21

EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study

Source: EyeGate Pharmaceuticals

06.11.21

Reed Exhibitions Unveils New Brand Identity

Source: The Vision Council

06.11.21

OcuGen to No Longer Pursue EUA for Covid-19 Vaccine Candidate Covaxin; Will Pursue Full Approval

Source: Ocugen

06.11.21

US to Buy 500 Million Doses of Pfizer, BioNTech COVID-19 Vaccine for Donation to Poorest Nations

Source: FirstWord

06.11.21

Ocuphire Added to the Russell Microcap Index

Source: Ocuphire Pharma

06.10.21

Glaukos Completes Patient Enrollment in US NDA Phase 3 Clinical Trials for iDose TR

Source: Glaukos

06.10.21

Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseases

Source: Oyster Point Pharma

View more stories